Latest & greatest articles for copd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on copd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on copd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for copd

1. Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease (Full text)

, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK. 14 Alan Turing Institute, London, UK. 15 Cambridge Clinical Trials Unit, Cambridge University Hospitals NHS Foundation Trust, Addenbrooke's Hospital, Cambridge, UK. 16 Department of Respiratory Medicine, Royal Brompton Hospital, London, UK. PMID: 32894757 DOI: Item in Clipboard Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease Jilles M Fermont et al. Age (...) Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease Short physical performance battery as a practical tool to assess mortality risk in chronic obstructive pulmonary disease - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features are temporarily unavailable. COVID-19 is an emerging, rapidly evolving

2020 EvidenceUpdates PubMed abstract

2. Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial

: DOI: Item in Clipboard Full-text links Cite Display options Display options Format Abstract Importance: Morphine is used as palliative treatment of chronic breathlessness in patients with advanced chronic obstructive pulmonary disease (COPD). Evidence on respiratory adverse effects and health status is scarce and conflicting. Objective: To assess the effects of regular, low-dose, oral sustained-release morphine on disease-specific health status (COPD Assessment Test; CAT), respiratory outcomes (...) Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial Effect of Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status: A Randomized Clinical Trial - PubMed This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features! Clipboard, Search History, and several other advanced features

2020 EvidenceUpdates

3. myCOPD for self-management of chronic obstructive pulmonary disease

to the clinical effectiveness of the technology. Further information about how the evidence for this briefing was selected is available on request by contacting mibs@nice.org.uk. Published evidence Published evidence Three studies are summarised in this briefing, including 2 randomised controlled trials and 1 observational study. In total, there were 167 people with chronic obstructive pulmonary disease (COPD) in these studies. The clinical evidence and its strengths and limitations is summarised (...) myCOPD for self-management of chronic obstructive pulmonary disease myCOPD for self-management of chronic obstructive pulmonary disease Medtech innovation briefing Published: 1 April 2020 www.nice.org.uk/guidance/mib214 pathways Summary Summary • The technology technology described in this briefing is myCOPD. It helps people with chronic obstructive pulmonary disease (COPD) to manage their symptoms and reduce the number of healthcare visits they need. It also helps the healthcare professionals

2020 NICE COVID-19 rapid evidence summary

4. Proton pump inhibitors for chronic obstructive pulmonary disease. (Abstract)

Proton pump inhibitors for chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is a common and progressive disease characterised by chronic cough, airflow limitation and recurrent exacerbations. Since COPD exacerbations are linked to rising mortality and reduced quality of life, the condition poses a substantial burden on individuals, society and the healthcare system. Effective management of COPD exacerbations that includes treatment of related conditions (...) COPD exacerbations, pneumonia and other serious adverse events. Secondary outcomes were quality of life, lung function test indices, acute respiratory infections and disease-specific adverse events. We extracted data on these outcome measures and entered into them into Review Manager software for analysis.The search identified 99 records, and we included one multicentre RCT that randomised 103 adults with COPD. The 12-month RCT compared an oral PPI (lansoprazole) and usual care versus usual care

2020 Cochrane

5. Chronic Obstructive Pulmonary Disease. (Abstract)

Chronic Obstructive Pulmonary Disease. Chronic obstructive pulmonary disease (COPD) is characterized by persistent respiratory symptoms and progressive airflow obstruction. Tobacco smoking is the leading cause but not the only one. A postbronchodilator FEV1-FVC ratio less than 0.70 is required for a diagnosis of COPD. Inhaler therapy is the backbone of treatment and should be complemented by a multifaceted management strategy that includes counseling and pharmacotherapy for smoking cessation (...) , pulmonary rehabilitation, treatment of comorbidities, administration of influenza and pneumococcal immunizations, and prescription of long-term oxygen therapy in hypoxemic patients.

2020 Annals of Internal Medicine

6. Addressing therapeutic questions to help Canadian physicians optimize COPD management for their patients during the Covid-19 pandemic

. Guan WJ, Liang WH, Zhao Y, et al. Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. Eur Respir J. 2020:2000547. 8. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). Respiratory Medicine. 2020. DOI: https://doi.org/10.1016/j.rmed.2020.105941 9. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020;395(10223 (...) distancing in the workplace setting is difficult to implement. Until we fully understand the risks associated with SARS-CoV-2 infection in patients with chronic lung disease we have placed a high value on limiting exposure based on prior experience with influenza. COPD Management – General Statement In the absence of direct or indirect data that use of current inhaled COPD therapies impacts the severity of SARS-CoV-2 infection, we recommend that maintenance and exacerbation management for COPD

2020 Canadian Thoracic Society

7. Inhaled Salbutamol Shortage – Mitigation Strategy for COPD

Inhaled Salbutamol Shortage – Mitigation Strategy for COPD CTS Guidance on Salbutamol Shortage - April 13, 2020 1 Inhaled Salbutamol Shortage – Mitigation Strategy for COPD April 13, 2020 Background 1) Health Canada and the pharmaceutical industry have identified that there was a three-fold increase in the demand for salbutamol inhalers in the first 3 weeks of March 2020. 2) This has resulted in a Tier 3 shortage, which by definition is “a situation when a manufacturer/importer is unable (...) to meet demand for the drug. A tier 3 shortage is a shortage with the greatest potential impact on the Canadian drug supply and healthcare systems by virtue of availability of alternate supplies, ingredients, or therapies.” 3) Restrictions have been put in place by wholesalers and distributors to limit the supply of salbutamol which means that most patients will receive only one salbutamol inhaler or a one month supply at a time . 4) It is possible that the surge in demand relates to individuals

2020 Canadian Thoracic Society

8. Baduanjin exercise for chronic obstructive pulmonary disease: an updated systematic review and meta-analysis

: Item in Clipboard Baduanjin exercise for chronic obstructive pulmonary disease: an updated systematic review and meta-analysis Ailing Cao et al. Clin Rehabil . 2020 Aug . Show details Clin Rehabil Actions . 2020 Aug;34(8):1004-1013. doi: 10.1177/0269215520926635. Epub 2020 Jun 10. Authors , , , Affiliation 1 Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. PMID: 32517512 DOI: Item (...) RSS Cancel RSS Link Copy Actions Cite Share Permalink Copy Page navigation Clin Rehabil Actions . 2020 Aug;34(8):1004-1013. doi: 10.1177/0269215520926635. Epub 2020 Jun 10. Baduanjin exercise for chronic obstructive pulmonary disease: an updated systematic review and meta-analysis , , , Affiliations Expand Affiliation 1 Department of Respiratory Medicine, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China. PMID: 32517512 DOI

2020 EvidenceUpdates

9. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. (Abstract)

Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-Severe COPD. Triple fixed-dose regimens of an inhaled glucocorticoid, a long-acting muscarinic antagonist (LAMA), and a long-acting β2-agonist (LABA) for chronic obstructive pulmonary disease (COPD) have been studied at single dose levels of inhaled glucocorticoid, but studies at two dose levels are lacking.In a 52-week, phase 3, randomized trial to evaluate the efficacy and safety of triple therapy at two dose levels (...) of inhaled glucocorticoid in patients with moderate-to-very-severe COPD and at least one exacerbation in the past year, we assigned patients in a 1:1:1:1 ratio to receive twice-daily inhaled doses of triple therapy (inhaled glucocorticoid [320 μg or 160 μg of budesonide], a LAMA [18 μg of glycopyrrolate], and a LABA [9.6 μg of formoterol]) or one of two dual therapies (18 μg of glycopyrrolate plus 9.6 μg of formoterol or 320 μg of budesonide plus 9.6 μg of formoterol). The primary end point

2020 NEJM

10. Home noninvasive positive-pressure ventilation reduces mortality and intubations in COPD with hypercapnia. (Abstract)

Home noninvasive positive-pressure ventilation reduces mortality and intubations in COPD with hypercapnia. Wilson ME, Dobler CC, Morrow AS, et al. Association of home noninvasive positive pressure ventilation with clinical outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2020;323:455-65. 32016309.

2020 Annals of Internal Medicine

11. Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. (Abstract)

Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among Older Adults. Smoking is a major risk factor for chronic obstructive pulmonary disease (COPD), yet much of COPD risk remains unexplained.To determine whether dysanapsis, a mismatch of airway tree caliber to lung size, assessed by computed tomography (CT), is associated with incident COPD among older adults and lung function decline in COPD.A retrospective cohort study of 2 community-based samples: the Multi-Ethnic Study (...) of Atherosclerosis (MESA) Lung Study, which involved 2531 participants (6 US sites, 2010-2018) and the Canadian Cohort of Obstructive Lung Disease (CanCOLD), which involved 1272 participants (9 Canadian sites, 2010-2018), and a case-control study of COPD: the Subpopulations and Intermediate Outcome Measures in COPD Study (SPIROMICS), which involved 2726 participants (12 US sites, 2011-2016).Dysanapsis was quantified on CT as the geometric mean of airway lumen diameters measured at 19 standard anatomic locations

2020 JAMA

12. Should You Recommend Inhaled Corticosteroids for This Patient With Chronic Obstructive Pulmonary Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. (Abstract)

Should You Recommend Inhaled Corticosteroids for This Patient With Chronic Obstructive Pulmonary Disease?: Grand Rounds Discussion From Beth Israel Deaconess Medical Center. Approximately 12 million adults in the United States receive a diagnosis of chronic obstructive pulmonary disease (COPD) each year, and it is the fourth leading cause of death. Chronic obstructive pulmonary disease refers to a group of diseases that cause airflow obstruction and a constellation of symptoms, including cough (...) , sputum production, and shortness of breath. The main risk factor for COPD is tobacco smoke, but other environmental exposures also may contribute. The GOLD (Global Initiative for Chronic Obstructive Lung Disease) 2020 Report aims to provide a nonbiased review of the current evidence for the assessment, diagnosis, and treatment of patients with COPD. To date, no conclusive evidence exists that any existing medications for COPD modify mortality. The mainstay of treatment for COPD is inhaled

2020 Annals of Internal Medicine

13. Pharmacologic Management of COPD: An Official ATS Clinical Practice Guideline

No Additional Therapy? Conclusions Summary of Recommendations In patients with chronic obstructive pulmonary disease (COPD) who complain of dyspnea or exercise intolerance, we recommend long-acting b 2 -agonist (LABA)/long-acting muscarinic antagonist (LAMA) combination therapy over LABA or LAMA monotherapy (strong recommendation, moderate certainty evidence). In patients with COPD who complain of dyspnea or exercise intolerance despite dual therapy with LABA/LAMA, we suggest the use of triple therapy (...) advise against the use of maintenance oral corticosteroid therapy (conditional recommendation, low certainty evidence). In individuals with COPD who experience advanced refractory dyspnea despite otherwise optimal therapy, we suggest that opioid-based therapy be considered for dyspnea management, within a personalized shared decision- making approach (conditional recommendation, very low certainty evidence). Introduction The Global Initiative for Chronic Obstructive Lung Disease 2019 report de?nes

2020 American Thoracic Society

14. Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. (Abstract)

Association Between Initiation of Pulmonary Rehabilitation After Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. Meta-analyses have suggested that initiating pulmonary rehabilitation after an exacerbation of chronic obstructive pulmonary disease (COPD) was associated with improved survival, although the number of patients studied was small and heterogeneity was high. Current guidelines recommend that patients enroll in pulmonary rehabilitation after hospital (...) discharge.To determine the association between the initiation of pulmonary rehabilitation within 90 days of hospital discharge and 1-year survival.This retrospective, inception cohort study used claims data from fee-for-service Medicare beneficiaries hospitalized for COPD in 2014, at 4446 acute care hospitals in the US. The final date of follow-up was December 31, 2015.Initiation of pulmonary rehabilitation within 90 days of hospital discharge.The primary outcome was all-cause mortality at 1 year. Time

2020 JAMA

15. Do Antibiotics Improve Patient Outcomes in Acute Exacerbations of Chronic Obstructive Pulmonary Disease? (Full text)

, and severity of COPD exacerbations. Thorax . 2002 ; 57 : 759–764 | | | , x 7 Seemungal, T., Harper-Owen, R., Bhowmik, A. et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med . 2001 ; 164 : 1618–1623 | | | , x 8 Sethi, S. Bacteria in exacerbations of chronic obstructive pulmonary disease: phenomenon or epiphenomenon?. Proc Am Thorac Soc . 2004 ; 1 : 109–114 | | | , x 9 Bafadhel, M., McKenna, S (...) ., Frei, A., Steurer-Stey, C.A. et al. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev . 2018 ; 10 : CD010257 Limitations of this meta-analysis include no consideration of underlying chronic obstructive pulmonary disease severity across trials because of poor reporting of lung function and other parameters. Studies were not limited to patients with suspected bacterial infection, who demonstrate the greatest benefit from antibiotics. Thus, the lack

2020 Annals of Emergency Medicine Systematic Review Snapshots PubMed abstract

16. COPD and COVID-19 for Healthcare Professionals

. There is no evidence to use or not to use oral or inhaled corticosteroids outside usual guidelines in COPD patients with COVID19. Antibiotics should be issued only if suspicion of secondary bacterial infection.” Please refer to that document. Please also refer to the NICE Rapid Guideline for the community-based care of patients with chronic obstructive pulmonary disease (COPD): https://www.nice.org.uk/guidance/ng168 This reiterates the importance of smoking cessation. Strongly encourage patients with COPD who (...) ), there is no routine indication to take rescue antibiotics or additional oral steroids. Do not offer patients with COPD a short course of oral corticosteroids and/or antibiotics to keep at home unless clinically indicated, as set out in the NICE guideline on chronic obstructive pulmonary disease in over 16s. There should be NO alteration to advanced rescue-pack prescribing or stockpiling inhalers. These seriously compromise the medicines supply chain and equitable access. Best practice at all times

2020 British Thoracic Society

17. Supervised pulmonary tele-rehabilitation versus pulmonary rehabilitation in severe COPD: a randomised multicentre trial (Full text)

Permalink Copy Page navigation Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial , , , , , , , , , , Affiliations Expand Affiliations 1 Respiratory Research Unit, Department of Respiratory Medicine, Hvidovre Hospital, Hvidovre, Denmark henrik.hansen.09@regionh.dk. 2 Department of Physical and Occupational Therapy, Bispebjerg Hospital (...) and Infectious Diseases, Hillerød Hospital, Hillerød, Denmark. 9 Department of Public Health, University of Copenhagen Faculty of Health Sciences, Copenhagen, Denmark. PMID: 32229541 DOI: Item in Clipboard Supervised Pulmonary Tele-Rehabilitation Versus Pulmonary Rehabilitation in Severe COPD: A Randomised Multicentre Trial Henrik Hansen et al. Thorax . 2020 May . Show details Thorax Actions . 2020 May;75(5):413-421. doi: 10.1136/thoraxjnl-2019-214246. Epub 2020 Mar 30. Authors

2020 EvidenceUpdates PubMed abstract

18. C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT (Full text)

C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT C-reactive protein point-of-care testing for safely reducing antibiotics for acute exacerbations of chronic obstructive pulmonary disease: the PACE RCT Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose (...) a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> 1)"> {{metadata.Title}} {{metadata.Headline}} Point-of-care testing resulted in a 20% absolute reduction in patient-reported antibiotic consumption over 4 weeks, without impairing chronic obstructive pulmonary disease health status. {{author}} {{($index , , , , , , , , , , , , , , , , , , , , & . Nick A Francis 1, * , David Gillespie 2 , Patrick White 3

2020 NIHR HTA programme PubMed abstract

19. Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. (Abstract)

Phosphodiesterase-4 inhibitors for chronic obstructive pulmonary disease. Chronic obstructive pulmonary disease (COPD) is associated with cough, sputum production or dyspnoea, and a reduction in lung function, quality of life, and life expectancy. Apart from smoking cessation, no other treatments that slow lung function decline are available. Roflumilast and cilomilast are oral phosphodiesterase-4 (PDE₄) inhibitors proposed to reduce the airway inflammation and bronchoconstriction seen in COPD (...) in the analyses for roflumilast (28 trials with 18,046 participants) or cilomilast (14 trials with 6457 participants) or tetomilast (1 trial with 84 participants), with a duration between six weeks and one year or longer. These trials included people across international study centres with moderate to very severe COPD (Global Initiative for Chronic Obstructive Lung Disease (GOLD) grades II to IV), with mean age of 64 years. We judged risks of selection bias, performance bias, and attrition bias as low overall

2020 Cochrane

20. Efficacy of statin therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis from 2008-2019. (Abstract)

Efficacy of statin therapy in chronic obstructive pulmonary disease: a systematic review and meta-analysis from 2008-2019. Statins produce significant hypolipidemic effects and reduce C-reactive protein (CRP) in patients with chronic obstructive pulmonary disease (COPD). It has been reported that statins did not prevent the acute exacerbation of COPD or improve clinical outcomes. We therefore analyzed the actual therapeutic effects of statins on COPD therapy during long-term clinical (...) trials.Relevant studies were retrieved from various databases from 2008 to 2019. For each study, odds ratios (ORs), mean difference (MD) and 95% confidence interval (95% CI) were assessed.Thirty-two studies were retrieved with 3,137 patients receiving statin therapy and 3,140 controls. Satins significantly increased exercise capacity (47.21, 95% CI: 20.79-73.63), lung FEV1 (4.02, 95% CI: 2.28-5.75), forced expiratory volume in 1s/forced vital capacity (FEV1/FVC) (3.56, 95% CI: 2.01-5.10) and high-density

2020 Panminerva medica